Therapeutic targeting of the oncostatin M receptor-β prevents inflammatory heart failure


Heart failure (HF) is a common and potentially deadly condition, which frequently develops as a consequence of various diseases of the heart. The incidence of heart failure continuously increases in aging societies illustrating the need for new therapeutic approaches. We recently discovered that continuous activation of oncostatin M (OSM), a cytokine of the interleukin-6 family that induces dedifferentiation of cardiomyocytes, promotes progression of heart failure in dilative cardiomyopathy. To evaluate whether inhibition of OSM signaling represents a meaningful therapeutic approach to prevent heart failure we attenuated OSM-receptor (Oβ) signaling in a mouse model of inflammatory dilative cardiomyopathy. We found that administration of an antibody directed against the extracellular domain of Oβ or genetic inactivation of a single allele of the Oβ gene reduced cardiomyocyte remodeling and dedifferentiation resulting in improved cardiac performance and increased survival. We conclude that pharmacological attenuation of long-lasting Oβ signaling is a promising strategy to treat different types and stages of HF that go along with infiltration by OSM-releasing inflammatory cells.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 199

This is the net price. Taxes to be calculated in checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7


  1. 1.

    Aasland D, Schuster B, Grotzinger J, Rose-John S, Kallen KJ (2003) Analysis of the leukemia inhibitory factor receptor functional domains by chimeric receptors and cytokines. Biochemistry 42:5244–5252. doi:10.1021/bi0263311

  2. 2.

    Ahmad S, Rai TS, Khullar M, Bahl A, Saikia UN, Thungapathra M, Kumar RM, Mahajan R, Talwar KK (2010) Decreased myocardial expression of dystrophin and titin mRNA and protein in dilated cardiomyopathy: possibly an adverse effect of TNF-alpha. J Clin Immunol 30:520–530. doi:10.1007/s10875-010-9388-3

  3. 3.

    Ahmed ST, Ivashkiv LB (2000) Inhibition of IL-6 and IL-10 signaling and Stat activation by inflammatory and stress pathways. J Immunol 165:5227–5237

  4. 4.

    Boengler K, Hilfiker-Kleiner D, Drexler H, Heusch G, Schulz R (2008) The myocardial JAK/STAT pathway: from protection to failure. Pharmacol Ther 120:172–185. doi:10.1016/j.pharmthera.2008.08.002

  5. 5.

    Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, Hansen RA, Morgan LC, Lohr KN (2008) Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 148:124–134

  6. 6.

    Feldmann M, Maini SR (2008) Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 223:7–19. doi:10.1111/j.1600-065X.2008.00626.x

  7. 7.

    Fischer P, Hilfiker-Kleiner D (2007) Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis. Basic Res Cardiol 102:279–297

  8. 8.

    Fourcin M, Chevalier S, Lebrun JJ, Kelly P, Pouplard A, Wijdenes J, Gascan H (1994) Involvement of gp130/interleukin-6 receptor transducing component in interleukin-11 receptor. Eur J Immunol 24:277–280. doi:10.1002/eji.1830240143

  9. 9.

    Frangogiannis NG (2012) Regulation of the inflammatory response in cardiac repair. Circ Res 110:159–173. doi:10.1161/CIRCRESAHA.111.243162

  10. 10.

    Gordon JW, Shaw JA, Kirshenbaum LA (2011) Multiple facets of NF-kappaB in the heart: to be or not to NF-kappaB. Circ Res 108:1122–1132. doi:10.1161/CIRCRESAHA.110.226928

  11. 11.

    Hein S, Block T, Zimmermann R, Kostin S, Scheffold T, Kubin T, Klovekorn WP, Schaper J (2009) Deposition of nonsarcomeric alpha-actinin in cardiomyocytes from patients with dilated cardiomyopathy or chronic pressure overload. Exp Clin Cardiol 14:e68–e75

  12. 12.

    Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374:1–20. doi:10.1042/BJ20030407

  13. 13.

    Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand J-L, Cohen-Tervaert JW, Drexler H, Filippatos G, Felix SB, Gullestad L, Hilfiker-Kleiner D, Janssens S, Latini R, Neubauer G, Paulus WJ, Pieske B, Ponikowski P, Schroen B, Schultheiss H-P, Tschope C, Van Bilsen M, Zannad F, McMurray J, Shah AM (2009) Inflammation as a therapeutic target in heart failure? A scientific statement from the translational research committee of the heart failure association of the European society of cardiology. Eur J Heart Fail 11:119–129. doi:10.1093/eurjhf/hfn043

  14. 14.

    Hintzen C, Quaiser S, Pap T, Heinrich PC, Hermanns HM (2009) Induction of CCL13 expression in synovial fibroblasts highlights a significant role of oncostatin M in rheumatoid arthritis. Arthr Rheum 60:1932–1943. doi:10.1002/art.24602

  15. 15.

    Kamimura D, Ishihara K, Hirano T (2003) IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol 149:1–38. doi:10.1007/s10254-003-0012-2

  16. 16.

    Kaye DM, Krum H (2007) Drug discovery for heart failure: a new era or the end of the pipeline? Nat Rev Drug Discov 6:127–139

  17. 17.

    Kleinbongard P, Heusch G, Schulz R (2010) TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol Ther 127:295–314. doi:10.1016/j.pharmthera.2010.05.002

  18. 18.

    Kolattukudy PE, Quach T, Bergese S, Breckenridge S, Hensley J, Altschuld R, Gordillo G, Klenotic S, Orosz C, Parker-Thornburg J (1998) Myocarditis induced by targeted expression of the MCP-1 gene in murine cardiac muscle. Am J Pathol 152:101–111

  19. 19.

    Kubin T, Poling J, Kostin S, Gajawada P, Hein S, Rees W, Wietelmann A, Tanaka M, Lorchner H, Schimanski S, Szibor M, Warnecke H, Braun T (2011) Oncostatin m is a major mediator of cardiomyocyte dedifferentiation and remodeling. Cell Stem Cell 9:420–432 pii: S1934-5909(11)00394-8

  20. 20.

    Kubin T, Tomars M, Fach C, Hein S, Bramlage P, Shim GJ, Scholz D, Kostin S, Zimmermann R, Elsasser A, Schaper W, Schaper J (2005) Transforming growth factor-beta1 downregulates beating frequency and remodeling of cultured rat adult cardiomyocytes. Cell Tissue Res 321:57–66

  21. 21.

    Maier HJ, Schips TG, Wietelmann A, Kruger M, Brunner C, Sauter M, Klingel K, Bottger T, Braun T, Wirth T (2012) Cardiomyocyte-specific I kappa B kinase (IKK)/NF-kappa B activation induces reversible inflammatory cardiomyopathy and heart failure. Proc Natl Acad Sci USA 109:11794–11799. doi:10.1073/pnas.1116584109

  22. 22.

    Packer M (1995) Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure. Eur Heart J 16(Suppl F):4–6

  23. 23.

    Person V, Kostin S, Suzuki K, Labeit S, Schaper J (2000) Antisense oligonucleotide experiments elucidate the essential role of titin in sarcomerogenesis in adult rat cardiomyocytes in long-term culture. J Cell Sci 113(Pt 21):3851–3859

  24. 24.

    Poling J, Gajawada P, Lorchner H, Polyakowa V, Szibor M, Bottger T, Warnecke H, Kubin T, Braun T (2012) The Janus face of OSM mediated cardiomyocyte dedifferentiation during cardiac repair and disease. Cell Cycle 11. pii:19024

  25. 25.

    Seta Y, Shan K, Bozkurt B, Oral H, Mann DL (1996) Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 2:243–249

  26. 26.

    Tanaka M, Hirabayashi Y, Sekiguchi T, Inoue T, Katsuki M, Miyajima A (2003) Targeted disruption of oncostatin M receptor results in altered hematopoiesis. Blood 102:3154–3162. doi:10.1182/blood-2003-02-0367

  27. 27.

    Weiss TW, Speidl WS, Kaun C, Rega G, Springer C, Macfelda K, Losert UM, Grant SL, Marro ML, Rhodes AD, Fuernkranz A, Bialy J, Ullrich R, Holzmann P, Pacher R, Maurer G, Huber K, Wojta J (2003) Glycoprotein 130 ligand oncostatin-M induces expression of vascular endothelial growth factor in human adult cardiac myocytes. Cardiovasc Res 59:628–638

  28. 28.

    Yoshida K, Taga T, Saito M, Suematsu S, Kumanogoh A, Tanaka T, Fujiwara H, Hirata M, Yamagami T, Nakahata T, Hirabayashi T, Yoneda Y, Tanaka K, Wang WZ, Mori C, Shiota K, Yoshida N, Kishimoto T (1996) Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci USA 93:407–411

  29. 29.

    Yoshimura A, Arai K (1996) Physician education: the erythropoietin receptor and signal transduction. Oncologist 1:337–339

Download references


The authors thank Jutta Wetzel, Kerstin Richter, Brigitte Matzke and Marion Wiesnet for excellent technical assistance. This work was supported by the Max-Planck-Society, the Excellence Cluster Cardiopulmonary System (ECCPS), the University of Giessen-Marburg Lung Center (UGMLC), and the German Center for Cardiovascular Research (DZHK). The authors declare that they have no conflicting commercial interests related to this work.

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Author information

Correspondence to Thomas Kubin or Thomas Braun.

Additional information

J. Pöling and P. Gajawada contributed equally.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 2 (MPG 9494 kb)

Supplementary material 1 (PDF 3637 kb)

Supplementary material 2 (MPG 9494 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Pöling, J., Gajawada, P., Richter, M. et al. Therapeutic targeting of the oncostatin M receptor-β prevents inflammatory heart failure. Basic Res Cardiol 109, 396 (2014).

Download citation


  • Dedifferentiation
  • Dilative cardiomyopathy
  • Cytokine
  • Cell survival program
  • Myoglobin
  • Insulin growth factor-1 (IGF-1)